Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | 1 | 2 | — | — | — | 2 |
Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Drug common name | IERAMILIMAB |
INN | ieramilimab |
Description | Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 2137049-37-5 |
RxCUI | — |
ChEMBL ID | CHEMBL4298009 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16419 |
UNII ID | OI8P0SFD4R (ChemIDplus, GSRS) |